Skip to main content

A Review on Pityriasis Rubra Pilaris

Abstract

Pityriasis rubra pilaris (PRP) is an idiopathic, papulosquamous inflammatory dermatosis. It is characterized by hyperkeratotic follicular papules coalescing into orange-red scaly plaques, islands of sparing, and palmoplantar keratoderma. PRP can be subdivided into six clinical subtypes according to Griffiths’ classification, based on age of onset, disease extent, prognosis, and other associated features. The sixth subtype of PRP occurs in individuals affected by HIV infection, and retroviral screening in all de novo cases of PRP is advised. Other reported associations include various infections, autoimmunity, drugs, and malignancies, although the true significance of these is still unclear. The genetic basis for familial cases, most commonly categorized under the fifth subtype, has been mapped to gain of function mutations in the caspase recruitment domain family, member 14 (CARD14) gene. Treatment of PRP remains a challenge to this day due to a paucity of high-quality evidence. Therapeutic regimens have been guided mostly by case reports and case series, with the mainstay of treatment being oral retinoids. Recently, biologics have emerged as a promising treatment for PRP. We present a review of the clinicopathologic features, pathogenesis, associated disorders, and treatment of PRP, with an emphasis and critical appraisal of the existing literature on the latter.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Tarral C. General psoriasis. Desquamation from the parts covered with hair. Theor Pract Treatise Dis Skin. 1835;2:648–9.

    Google Scholar 

  2. 2.

    Devergie MGA. Pityriasis pilaris, maladie de peau non decrite par les dermatologistes. Gaz Hebd Med Chir. 1856;3:197–201.

    Google Scholar 

  3. 3.

    Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol. 1980;5:105–12.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Sehgal VN, Jain MK, Mathur RP. Pityriasis rubra pilaris in Indians. Br J Dermatol. 1989;121:821–2.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Gelmetti C, Schiuma AA, Cerri D, Gianotti F. Pityriasis rubra pilaris in childhood: a long-term study of 29 cases. Pediatr Dermatol. 1986;3:446–51.

    Article  Google Scholar 

  6. 6.

    Miralles ES, Núñez M, De Las Heras ME, Pérez B, Moreno R, Ledo A. Pityriasis rubra pilaris and human immunodeficiency virus infection. Br J Dermatol. 1995;133:990–3.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol. 2010;11:157–70.

    PubMed  Article  Google Scholar 

  8. 8.

    Conaghan PG, Sommer S, McGonagle D, Veale D, Waldmann H, Hale G, et al. The relationship between pityriasis rubra pilaris and inflammatory arthritis: case report and response of the arthritis to anti-tumor necrosis factor immunotherapy. Arthritis Rheum. 1999;42:1998–2001.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Wood GS, Reizner GT. Other papulosquamous disorders. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. Philadelphia: Elsevier Ltd (Saunders); 2012.

    Google Scholar 

  10. 10.

    González-López A, Velasco E, Pozo T, Del Villar A. HIV-associated pityriasis rubra pilaris responsive to triple antiretroviral therapy. Br J Dermatol. 1999;140:931–4.

    PubMed  Article  Google Scholar 

  11. 11.

    Martin AG, Weaver CC, Cockerell CJ, Berger TG. Pityriasis rubra pilaris in the setting of HIV infection: clinical behaviour and association with explosive cystic acne. Br J Dermatol. 1992;126:617–20.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Blasdale C, Turner RJ, Leonard N, Ong ELC, Lawrence CM. Spontaneous clinical improvement in HIV-associated follicular syndrome. Clin Exp Dermatol. 2004;29:480–2.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Fuchs-Telem D, Sarig O, van Steensel MAM, Isakov O, Israeli S, Nousbeck J, et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet. 2012;91:163–70.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Vanderhooft SL, Francis JS, Holbrook KA, Dale BA, Fleckman P. Familial pityriasis rubra pilaris. Arch Dermatol. 1995;131:448–53.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Vasher M, Smithberger E, Lien MH, Fenske NA. Familial pityriasis rubra pilaris: report of a family and therapeutic response to etanercept. J Drugs Dermatol JDD. 2010;9:844–50.

    PubMed  Google Scholar 

  16. 16.

    Jordan CT, Cao L, Roberson EDO, Pierson KC, Yang C-F, Joyce CE, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012;90:784–95.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Takeichi T, Sugiura K, Nomura T, Sakamoto T, Ogawa Y, Oiso N, et al. Pityriasis rubra pilaris type V as an autoinflammatory disease by CARD14 mutations. JAMA Dermatol. 2017;153:66–70.

    PubMed  Article  Google Scholar 

  18. 18.

    Eytan O, Qiaoli L, Nousbeck J, van Steensel MA, Burger B, Hohl D, et al. Increased epidermal expression and absence of mutations in CARD14 in a series of patients with sporadic pityriasis rubra pilaris. Br J Dermatol. 2014;170:1196–8.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Frazier CN, Ch’uan-K’uei H. Cutaneous lesions associated with a deficiency in vitamin A in man. Arch Intern Med. 1931;48:507–14.

    CAS  Article  Google Scholar 

  20. 20.

    Frazier CN, Ch’uan-K’uei H. Nature and distribution according to age of cutaneous manifestations of vitamin A deficiency: a study of two hundred and seven cases. Arch Dermatol Syphilol. 1936;33:825–52.

    CAS  Article  Google Scholar 

  21. 21.

    Loewenthal LJA. A new cutaneous manifestation in the syndrome of vitamin A deficiency. Arch Dermatol Syphilol. 1933;28:700–8.

    Article  Google Scholar 

  22. 22.

    Griffiths WA. Vitamin A and pityriasis rubra pilaris. J Am Acad Dermatol. 1982;7:555.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Gross DA, Landau JW, Newcomer VD. Pityriasis rubra pilaris: report of a case and analysis of the literature. Arch Dermatol. 1969;99:710–6.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Finzi AF, Altomare G, Bergamaschini L, Tucci A. Pityriasis rubra pilaris and retinol-binding protein. Br J Dermatol. 1981;104:253–6.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Van Voorst Vader PC, Van Oostveen F, Houthoff HJ, Marrink J. Pityriasis rubra pilaris, vitamin A and retinol-binding protein: a case study. Acta Derm Venereol. 1984;64:430–2.

    PubMed  Google Scholar 

  26. 26.

    Stoll DM, King LE, Chytil F. Serum levels of retinol binding protein in patients with pityriasis rubra pilaris. Br J Dermatol. 1983;108:375.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Vahlquist A. Retinol binding protein and pityriasis rubra pilaris [letter]. Br J Dermatol. 1982;107:125–6.

    Article  Google Scholar 

  28. 28.

    Magro CM, Crowson AN. The clinical and histomorphological features of pityriasis rubra pilaris. A comparative analysis with psoriasis. J Cutan Pathol. 1997;24:416–24.

    CAS  PubMed  Article  Google Scholar 

  29. 29.

    Yamamoto T, Yokoyama A. Lymphocyte response to superantigen in a patient with childhood-onset pityriasis rubra pilaris. Int J Dermatol. 1999;38:639–40.

    CAS  PubMed  Google Scholar 

  30. 30.

    Betlloch I, Ramón R, Silvestre JF, Carnero L, Albares MP, Bañuls J. Acute juvenile pityriasis rubra pilaris: a superantigen mediated disease? Pediatr Dermatol. 2001;18:411–4.

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Kawara S, Miyake M, Oiso N, Kawada A. Pityriasis rubra pilaris with preceding cytomegalovirus infection. Dermatology. 2009;219:350–2.

    PubMed  Article  Google Scholar 

  32. 32.

    Wang T, Liu J, Liu Y, Zheng H. Pityriasis rubra pilaris (PRP) with preceding Epstein-Barr virus infection: a new type PRP with non-HIV virus infection? Chin Med J (Engl). 2014;127:2391.

    PubMed  Google Scholar 

  33. 33.

    Erdem T, Atasoy M, Aliagaoglu C, Melikoglu M, Yildirim U. Pityriasis rubra pilaris in association with hepatitis A. Saudi Med J. 2006;27:1421–2.

    PubMed  Google Scholar 

  34. 34.

    Ertam I, Sezgin AO, Kazandi A, Dereli T, Unal I. A case of juvenile pityriasis rubra pilaris: could varicella be an aetiological agent? Clin Exp Dermatol. 2009;34:e1012–3.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Das JK, Gangopadhyay AK, Sengupta S. Pityriasis rubra pilaris with Koebner’s isomorphic phenomenon. Indian J Dermatol Venereol Leprol. 2010;76:194–6.

    PubMed  Article  Google Scholar 

  36. 36.

    Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH. Pityriasis rubra pilaris in children. J Am Acad Dermatol. 2002;47:386–9.

    PubMed  Article  Google Scholar 

  37. 37.

    Clayton BD, Jorizzo JL, Hitchcock MG, Fleischer AB, Williford PM, Feldman SR, et al. Adult pityriasis rubra pilaris: a 10-year case series. J Am Acad Dermatol. 1997;36:959–64.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Yang C-C, Shih I-H, Lin W-L, Yu Y-S, Chiu H-C, Huang P-H, et al. Juvenile pityriasis rubra pilaris: report of 28 cases in Taiwan. J Am Acad Dermatol. 2008;59:943–8.

    PubMed  Article  Google Scholar 

  39. 39.

    Męcińska-Jundziłł K, Białecka A, Adamska U, Skrzeczko-Kwela E, Czajkowski R. Photosensitive pityriasis rubra pilaris. Postepy Dermatol Alergol. 2016;33:239–42.

    PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Iredale HE, Meggitt SJ. Photosensitive pityriasis rubra pilaris. Clin Exp Dermatol. 2006;31:36–8.

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Yaniv R, Barzilai A, Trau H. Pityriasis rubra pilaris exacerbated by ultraviolet B phototherapy. Dermatology. 1994;189:313.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Marguery MC, Durand-Malgouyres C, Bayle-Lebey P, Dupin P, Bazex J. Photosensitive and phototriggered pityriasis rubra pilaris. Photodermatol Photoimmunol Photomed. 1994;10:42–5.

    CAS  PubMed  Google Scholar 

  43. 43.

    Evangelou G, Murdoch SR, Palamaras I, Rhodes LE. Photoaggravated pityriasis rubra pilaris. Photodermatol Photoimmunol Photomed. 2005;21:272–4.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Kaskel P, Grundmann-Kollmann M, Schiller PI, Krähn G, Pillekamp H, Peter RU, et al. Bath-PUVA as a treatment for Pityriasis rubra pilaris provoked by ultraviolet B. Br J Dermatol. 1999;140:769–70.

    CAS  PubMed  Google Scholar 

  45. 45.

    Jack A, Mauro MJ, Ehst BD. Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib. J Am Acad Dermatol. 2013;69:e249–50.

    PubMed  Article  Google Scholar 

  46. 46.

    Paz C, Querfeld C, Shea CR. Sorafenib-induced eruption resembling pityriasis rubra pilaris. J Am Acad Dermatol. 2011;65:452–3.

    PubMed  Article  Google Scholar 

  47. 47.

    Plana A, Carrascosa JM, Vilavella M, Ferrandiz C. Pityriasis rubra pilaris-like reaction induced by imatinib. Clin Exp Dermatol. 2013;38:520–2.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Stalling SS, Vu JR, English JC. Telaprevir-induced pityriasis rubra pilaris-like drug eruption. Arch Dermatol. 2012;148:1215–7.

    PubMed  Article  Google Scholar 

  49. 49.

    Cheung EJ, Jedrych JJ, English JC. Sofosbuvir-induced erythrodermic pityriasis rubra pilaris-like drug eruption. J Drugs Dermatol. 2015;14:1161–2.

    CAS  PubMed  Google Scholar 

  50. 50.

    Yang FC, Jessup C, Dahiya M, Reynolds R. Pityriasis rubra pilaris exacerbation with topical use of imiquimod. Int J Dermatol. 2008;47:1076–8.

    PubMed  Article  Google Scholar 

  51. 51.

    Atanaskova MN, Dawes D, Sood A, Bergfeld W. Acantholytic pityriasis rubra pilaris. Case Rep Dermatol Med. 2011;2011:412684.

    Google Scholar 

  52. 52.

    Gómez-Moyano E, Crespo-Erchiga A, Vera Casaño A, Sanz Trelles A. Pityriasis rubra pilaris with focal acantholytic dyskeratosis during treatment with imiquimod 5% cream [in Spanish]. Actas Dermosifiliogr. 2010;101:898–900.

    PubMed  Article  Google Scholar 

  53. 53.

    López-Ferrer A, Dalmau J, Fernández-Figueras MT, Puig L. Pityriasis rubra pilaris triggered by photodynamic therapy with response to tumor necrosis factor α-blocking agents and acitretin. Cutis. 2014;93:E6–7.

    PubMed  Google Scholar 

  54. 54.

    Waldorf DS, Hambrick GW. Vitamin A—responsive pityriasis rubra pilaris with myasthenia gravis. Arch Dermatol. 1965;92:424–7.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Gül U, Gönül M, Kiliç A, Soylu S, Koçak O, Gönen B, et al. A case of pityriasis rubra pilaris associated with sacroileitis and autoimmune thyroiditis. J Eur Acad Dermatol Venereol. 2008;22:889–90.

    PubMed  Article  Google Scholar 

  56. 56.

    Orlandini V, Cogrel O, Doutre MS, Beylot C, Beylot-Barry M. Pityriasis rubra pilaris and hypothyroidism. Efficacy of thyroid hormone replacement therapy in skin recovery. Br J Dermatol. 2007;156:606–7.

    CAS  PubMed  Article  Google Scholar 

  57. 57.

    Franzotti AM, Avelar JCD, Cardoso TA, Pires MC, Vidigal Mdo R. Pityriasis Rubra Pilar and hypothyroidism. An Bras Dermatol. 2014;89:497–500.

    PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Randle HW, Winkelmann RK. Pityriasis rubra pilaris and celiac sprue with malabsorption. Cutis. 1980;25:626–7.

    CAS  PubMed  Google Scholar 

  59. 59.

    Hazini AR, Rongioletti F, Rebora A. Pityriasis rubra pilaris and vitiligo in Down’s syndrome. Clin Exp Dermatol. 1988;13:334–5.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Bar-Ilan E, Gat A, Sprecher E, Zeeli T. Paraneoplastic pityriasis rubra pilaris: case report and literature review. Clin Exp Dermatol. 2017;42:54–7.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Sharma S, Weiss GR, Paulger B. Pityriasis rubra pilaris as an initial presentation of hepatocellular carcinoma. Dermatology. 1997;194:166–7.

    CAS  PubMed  Article  Google Scholar 

  62. 62.

    Batinac T, Kujundzić M, Peternel S, Cabrijan L, Troselj-Vukić B, Petranović D. Pityriasis rubra pilaris in association with laryngeal carcinoma. Clin Exp Dermatol. 2009;34:e917–9.

    CAS  PubMed  Article  Google Scholar 

  63. 63.

    Kurzydlo A-M, Gillespie R. Paraneoplastic pityriasis rubra pilaris in association with bronchogenic carcinoma. Australas J Dermatol. 2004;45:130–2.

    PubMed  Article  Google Scholar 

  64. 64.

    Remedios IM, Jensen JD, Beckum K, McKay K, Kissel R. Paraneoplastic pityriasis rubra pilaris as the presenting manifestation of metastatic squamous cell carcinoma. J Drugs Dermatol. 2014;13:610–2.

    PubMed  Google Scholar 

  65. 65.

    Garretson CB, Machan ML, Krejci-Manwaring J, Aires D, Tonkovic-Capin V. Adenocarcinoma of the lung associated with pityriasis rubra pilaris [letter]. Dermatol Online J. 2011;17:14.

    PubMed  Google Scholar 

  66. 66.

    Batchelor RJ, Yung A, Merchant W, Goodfield MJD. Pityriasis rubra pilaris as the initial presentation of renal cell carcinoma? Clin Exp Dermatol. 2005;30:442–3.

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Reinhardt LA, Rosen T. Pityriasis rubra pilaris as the initial manifestation of leukemia. Cutis. 1983;31:100–2.

    CAS  PubMed  Google Scholar 

  68. 68.

    Sánchez-Regaña M, López-Gil F, Salleras M, Umbert P. Pityriasis rubra pilaris as the initial manifestation of internal neoplasia. Clin Exp Dermatol. 1995;20:436–8.

    PubMed  Article  Google Scholar 

  69. 69.

    Vitiello M, Miteva M, Romanelli P, Castaneda J, Garces-Milanes D, Kirsner R, et al. Pityriasis rubra pilaris: was it the first manifestation of colon cancer in a patient with pre-existing psoriasis? J Am Acad Dermatol. 2013;68:e43–4.

    PubMed  Article  Google Scholar 

  70. 70.

    Piamphongsant T, Akaraphant R. Pityriasis rubra pilaris: a new proposed classification. Clin Exp Dermatol. 1994;19:134–8.

    CAS  PubMed  Article  Google Scholar 

  71. 71.

    Ingram J. Pityriasis rubra pilaris. Aust J Dermatol. 1960;5:177–84.

    Article  Google Scholar 

  72. 72.

    Ko CJ, Milstone LM, Choi J, McNiff JM. Pityriasis rubra pilaris: the clinical context of acantholysis and other histologic features. Int J Dermatol. 2011;50:1480–5.

    PubMed  Article  Google Scholar 

  73. 73.

    Rashidghamat E, Griffiths WAD, Mellerio JE, Robson A. Pityriasis rubra pilaris with histologic features of lichen nitidus. J Am Acad Dermatol. 2015;73:336–7.

    PubMed  Article  Google Scholar 

  74. 74.

    Marrouche N, Kurban M, Kibbi A-G, Abbas O. Pityriasis rubra pilaris: clinicopathological study of 32 cases from Lebanon. Int J Dermatol. 2014;53:434–9.

    PubMed  Article  Google Scholar 

  75. 75.

    Avitan-Hersh E, Bergman R. The incidence of acantholysis in pityriasis rubra pilaris-histopathological study using multiple-step sections and clinicopathologic correlations. Am J Dermatopathol. 2015;37:755–8.

    PubMed  Article  Google Scholar 

  76. 76.

    Braun-Falco O, Ryckmanns F, Schmoeckel C, Landthaler M. Pityriasis rubra pilaris: a clinico-pathological and therapeutic study with special reference to histochemistry, autoradiography, and electron microscopy. Arch Dermatol Res. 1983;275:287–95.

    CAS  PubMed  Article  Google Scholar 

  77. 77.

    Chan H, Liu FT, Naguwa S. A review of pityriasis rubra pilaris and rheumatologic associations. Clin Dev Immunol. 2004;11:57–60.

    PubMed  PubMed Central  Article  Google Scholar 

  78. 78.

    Marchetti MA, Greer KE. Pityriasis rubra pilaris treated with methotrexate resolving with an erythema gyratum repens-like appearance. J Am Acad Dermatol. 2013;69:e32–3.

    PubMed  Article  Google Scholar 

  79. 79.

    Almaani N, Robson A, Sarkany R, Griffiths WAD. Erythema gyratum repens associated with pityriasis rubra pilaris. Clin Exp Dermatol. 2011;36:161–4.

    CAS  PubMed  Article  Google Scholar 

  80. 80.

    Gebauer K, Singh G. Resolving pityriasis rubra pilaris resembling erythema gyratum repens. Arch Dermatol. 1993;129:917–8.

    CAS  PubMed  Article  Google Scholar 

  81. 81.

    Caldarola G, Zampetti A, De Simone C, Massi G, Amerio P, Feliciani C. Circumscribed pityriasis rubra pilaris type IV. Clin Exp Dermatol. 2007;32:471–2.

    CAS  PubMed  Article  Google Scholar 

  82. 82.

    Albert MR, Mackool BT. Pityriasis rubra pilaris. Int J Dermatol. 1999;38:1–11.

    CAS  PubMed  Article  Google Scholar 

  83. 83.

    Lin W-L, Lin W-C, Shih I-H, Yang L-C, Hong H-S. Juvenile pityriasis rubra pilaris in Chang Gung Memorial Hospital, Taipei and Linkou: a retrospective study in the past ten years. Dermatol Sin. 2007;25:248–55.

    Google Scholar 

  84. 84.

    Karimian-Teherani D, Parissa M, Tanew A. Response of juvenile circumscribed pityriasis rubra pilaris to topical tazarotene treatment. Pediatr Dermatol. 2008;25:125–6.

    PubMed  Article  Google Scholar 

  85. 85.

    Van de Kerkhof PC, Steijlen PM. Topical treatment of pityriasis rubra pilaris with calcipotriol. Br J Dermatol. 1994;130:675–8.

    PubMed  Article  Google Scholar 

  86. 86.

    Jaimovich L, Mordoh A, Schroh R. Treatment of circumscribed juvenile type of pityriasis rubra pilaris with calcipotriol. J Dermatol Treat. 1997;8:211–2.

    Article  Google Scholar 

  87. 87.

    Gregoriou S, Argyriou G, Christofidou E, Vranou A, Rigopoulos D. Treatment of pityriasis rubra pilaris with pimecrolimus cream 1%. J Drugs Dermatol. 2007;6:340–2.

    PubMed  Google Scholar 

  88. 88.

    Goldsmith LA, Weinrich AE, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol. 1982;6:710–5.

    CAS  PubMed  Article  Google Scholar 

  89. 89.

    Borok M, Lowe NJ. Pityriasis rubra pilaris. Further observations of systemic retinoid therapy. J Am Acad Dermatol. 1990;22:792–5.

    CAS  PubMed  Article  Google Scholar 

  90. 90.

    Sanchez-Regana M, Creus L, Umbert P. Pityriasis rubra pilaris. A long-term study of 25 cases. Eur J Dermatol. 1994;4:593–7.

    Google Scholar 

  91. 91.

    Dicken CH. Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol. 1994;31:997–9.

    CAS  PubMed  Article  Google Scholar 

  92. 92.

    Gemmeke A, Schönlebe J, Koch A, Wollina U. Pityriasis rubra pilaris–a retrospective single center analysis over eight years [in English, German]. J Dtsch Dermatol Ges. 2010;8:439–44.

    PubMed  Google Scholar 

  93. 93.

    Eastham AB, Femia AN, Qureshi A, Vleugels RA. Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center. JAMA Dermatol. 2014;150:92–4.

    PubMed  Article  Google Scholar 

  94. 94.

    Lee HS, Lee E-S. Classic juvenile pityriasis rubra pilaris treated with oral alitretinoin. Ann Dermatol. 2016;28:388–90.

    PubMed  PubMed Central  Article  Google Scholar 

  95. 95.

    Yun CH, Kim JS, Ryu HR, Kim JH, Baek JO, Lee JR, et al. Circumscribed juvenile pityriasis rubra pilaris responsive to alitretinoin. Dermatol Ther. 2016;29:81–3.

    PubMed  Article  Google Scholar 

  96. 96.

    Pampín A, Gómez-de la Fuente E, Caro Gutiérrez MD, López-Estebaranz JL. Successful treatment of atypical adult pityriasis rubra pilaris with oral alitretinoin. J Am Acad Dermatol. 2013;69:e105–6.

    PubMed  Article  Google Scholar 

  97. 97.

    Schmitt L, Inhoff O, Dippel E. Oral alitretinoin for the treatment of recalcitrant pityriasis rubra pilaris. Case Rep Dermatol. 2011;3:85–8.

    PubMed  PubMed Central  Article  Google Scholar 

  98. 98.

    Molin S, Ruzicka T. Treatment of refractory pityriasis rubra pilaris with oral alitretinoin: case report. Br J Dermatol. 2010;163:221–3.

    CAS  PubMed  Google Scholar 

  99. 99.

    Amann PM, Susic M, Glüder F, Berger H, Krapf W, Löffler H. Alitretinoin (9-cis retinoic acid) is effective against pityriasis rubra pilaris: a retrospective clinical study. Acta Derm Venereol. 2015;95:329–31.

    CAS  PubMed  Article  Google Scholar 

  100. 100.

    Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol. 2003;49:171–82 (quiz 183–186).

    PubMed  Article  Google Scholar 

  101. 101.

    Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49:S1–37.

    PubMed  Article  Google Scholar 

  102. 102.

    Ormerod AD, Campalani E, Goodfield MJ, BAD Clinical Standards Unit. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol. 2010;162:952–63.

    CAS  PubMed  Article  Google Scholar 

  103. 103.

    Chapalain V, Beylot-Barry M, Doutre MS, Beylot C. Treatment of pityriasis rubra pilaris: a retrospective study of 14 patients. J Dermatol Treat. 1999;10:113–7.

    CAS  Article  Google Scholar 

  104. 104.

    van Dooren-Greebe RJ, van de Kerkhof PC. Extensive extraspinal hyperostoses after long-term oral retinoid treatment in a patient with pityriasis rubra pilaris. J Am Acad Dermatol. 1995;32:322–5.

    PubMed  Article  Google Scholar 

  105. 105.

    Beck HI, Foged EK. Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis. Dermatologica. 1983;167:94–6.

    CAS  PubMed  Article  Google Scholar 

  106. 106.

    Zachariae H. Dangers of methotrexate/etretinate combination therapy [letter]. Lancet. 1988;1:422.

    CAS  PubMed  Article  Google Scholar 

  107. 107.

    Lim JT, Tham SN. Pityriasis rubra pilaris in Singapore. Clin Exp Dermatol. 1991;16:181–4.

    CAS  PubMed  Article  Google Scholar 

  108. 108.

    Khoo L, Asawanonda P, Grevelink SA, Taylor CR. Narrow-band UVB-associated lesional blisters in pityriasis rubra pilaris. J Am Acad Dermatol. 1999;41:803–4.

    CAS  PubMed  Article  Google Scholar 

  109. 109.

    Betto P, Vassilopoulou A, Colombari R, Veller-Fornasa C. Acute juvenile pityriasis rubra pilaris: a case report after mononucleosis infection. G Ital Dermatol Venereol. 2008;143:271–3.

    CAS  PubMed  Google Scholar 

  110. 110.

    Massa AF, Vasconcelos P, Soares de Almeida L, Filipe P. Pityriasis rubra pilaris mixed type III/IV successfully treated with narrow band-ultraviolet B. Indian J Dermatol Venereol Leprol. 2015;81:435.

    CAS  PubMed  Article  Google Scholar 

  111. 111.

    Herbst RA, Vogelbruch M, Ehnis A, Kiehl P, Kapp A, Weiss J. Combined ultraviolet al radiation and acitretin therapy as a treatment option for pityriasis rubra pilaris. Br J Dermatol. 2000;142:574–5.

    CAS  PubMed  Article  Google Scholar 

  112. 112.

    Neess CM, Hinrichs R, Dissemond J, Herrmann G, Poswig A, Servera-Llanras M, et al. Treatment of pruritus by capsaicin in a patient with pityriasis rubra pilaris receiving RE-PUVA therapy. Clin Exp Dermatol. 2000;25:209–11.

    CAS  PubMed  Article  Google Scholar 

  113. 113.

    Kirby B, Watson R. Pityriasis rubra pilaris treated with acitretin and narrow-band ultraviolet B (Re-TL-01). Br J Dermatol. 2000;142:376–7.

    CAS  PubMed  Article  Google Scholar 

  114. 114.

    Booth AV, Ma L. Pityriasis rubra pilaris, type 1. Dermatol Online J. 2005;11:9.

    PubMed  Google Scholar 

  115. 115.

    Vergilis-Kalner IJ, Mann DJ, Wasserman J, Petronic-Rosic V, Tsoukas MM. Pityriasis rubra pilaris sensitive to narrow band-ultraviolet B light therapy. J Drugs Dermatol. 2009;8:270–3.

    PubMed  Google Scholar 

  116. 116.

    Cox V, Lesesky EB, Garcia BD, O’Grady TC. Treatment of juvenile pityriasis rubra pilaris with etanercept. J Am Acad Dermatol. 2008;59:S113–4.

    PubMed  Article  Google Scholar 

  117. 117.

    Walling HW, Swick BL. Pityriasis rubra pilaris responding rapidly to adalimumab. Arch Dermatol. 2009;145:99–101.

    PubMed  Article  Google Scholar 

  118. 118.

    Ivanova K, Itin P, Haeusermann P. Pityriasis rubra pilaris: treatment with biologics—a new promising therapy? Dermatology. 2012;224:120–5.

    PubMed  Article  Google Scholar 

  119. 119.

    Adnot-Desanlis L, Antonicelli F, Tabary T, Bernard P, Reguiaï Z. Effectiveness of infliximab in pityriasis rubra pilaris is associated with pro-inflammatory cytokine inhibition. Dermatology. 2013;226:41–6.

    CAS  PubMed  Article  Google Scholar 

  120. 120.

    Ruiz Villaverde R, Sánchez Cano D. Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy. Eur J Dermatol. 2010;20:630–1.

    PubMed  Google Scholar 

  121. 121.

    Müller H, Gattringer C, Zelger B, Höpfl R, Eisendle K. Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. J Am Acad Dermatol. 2008;59:S65–70.

    PubMed  Article  Google Scholar 

  122. 122.

    Petrof G, Almaani N, Archer CB, Griffiths WA, Smith CH. A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists. J Eur Acad Dermatol Venereol. 2013;27:e131–5.

    CAS  PubMed  Article  Google Scholar 

  123. 123.

    Karadag AS, Kavala M, Ozlu E, Ozkanlı S, Zindancı İ, Turkoglu Z. Erythrodermic pityriasis rubra pilaris: dramatic response to infliximab therapy. Indian J Dermatol Venereol Leprol. 2016;82:112.

    PubMed  Article  Google Scholar 

  124. 124.

    Mattox AR, Chappell JA, Hurley MY. New-onset vitiligo during long-term, stable infliximab treatment of pityriasis rubra pilaris. J Drugs Dermatol. 2013;12:217–9.

    PubMed  Google Scholar 

  125. 125.

    Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg. 2003;7:382–6.

    PubMed  Article  Google Scholar 

  126. 126.

    Barth D, Harth W, Treudler R, Simon JC. Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate. J Dtsch Dermatol Ges. 2009;7:1071–4.

    PubMed  Google Scholar 

  127. 127.

    Liao WC, Mutasim DF. Infliximab for the treatment of adult-onset pityriasis rubra pilaris. Arch Dermatol. 2005;141:423–5.

    PubMed  Article  Google Scholar 

  128. 128.

    Manoharan S, White S, Gumparthy K. Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab. Australas J Dermatol. 2006;47:124–9.

    PubMed  Article  Google Scholar 

  129. 129.

    Ruiz-Genao DP, Lopez-Estebaranz JL, Naz-Villalba E, Gamo-Villegas R, Calzado-Villarreal L, Pinedo-Moraleda F. Pityriasis rubra pilaris successfully treated with infliximab. Acta Derm Venereol. 2007;87:552–3.

    PubMed  Article  Google Scholar 

  130. 130.

    Zirbs M, Kigitsidou E, Seifert F, Ring J, Brockow K. Successful treatment with infliximab despite positive tuberculosis ELISpot results in a patient with pityriasis rubra pilaris taking prophylactic isoniazid. Clin Exp Dermatol. 2011;36:808–9.

    CAS  PubMed  Article  Google Scholar 

  131. 131.

    Dessinioti C, Vergou T, Moustou E, Katsambas A, Antoniou C. Long-term infliximab treatment for refractory type III juvenile pityriasis rubra pilaris. Eur J Dermatol. 2011;21:599–600.

    PubMed  Google Scholar 

  132. 132.

    Garcovich S, Di Giampetruzzi AR, Antonelli G, Garcovich A, Didona B. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series. J Eur Acad Dermatol Venereol. 2010;24:881–4.

    CAS  PubMed  Article  Google Scholar 

  133. 133.

    Ruzzetti M, Saraceno R, Carboni I, Papoutsaki M, Chimenti S. Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab. J Eur Acad Dermatol Venereol. 2008;22:117–8.

    CAS  PubMed  Google Scholar 

  134. 134.

    Vujic I, Richter L, Bartsch K, Monshi B, Rappersberger K. Pityriasis rubra pilaris types 1 and 2: different responses to treatment with TNF-alpha antagonists. Eur J Dermatol. 2013;23:895–6.

    PubMed  Google Scholar 

  135. 135.

    Lu R, George SJ, Hsu S. Pityriasis rubra pilaris: failure of combination treatment with acitretin and infliximab. Dermatol Online J. 2006;12:18.

    PubMed  Google Scholar 

  136. 136.

    Salman A, Sonmez Y, Sahin H, Unal AU, Direskeneli H, Cinel L, et al. Infliximab-induced cutaneous eruption resembling pityriasis rubra pilaris in a patient with Takayasu’s arteritis. Dermatol Ther. 2017;30:e12443.

    Article  Google Scholar 

  137. 137.

    Kim JH, Park M-C, Kim S-C. Etanercept-induced clinical remission of type II pityriasis rubra pilaris with rheumatoid arthritis. Acta Derm Venereol. 2012;92:399–400.

    CAS  PubMed  Article  Google Scholar 

  138. 138.

    Guedes R, Leite L. Therapeutic hotline. Treatment of pityriasis rubra pilaris with etanercept. Dermatol Ther. 2011;24:285–6.

    PubMed  Article  Google Scholar 

  139. 139.

    Seckin D, Tula E, Ergun T. Successful use of etanercept in type I pityriasis rubra pilaris. Br J Dermatol. 2008;158:642–4.

    CAS  PubMed  Article  Google Scholar 

  140. 140.

    Davis KF, Wu JJ, Murase JE, Rosenberg FR, Sorenson EP, Meshkinpour A. Clinical improvement of pityriasis rubra pilaris with combination etanercept and acitretin therapy. Arch Dermatol. 2007;143:1597–9.

    PubMed  Google Scholar 

  141. 141.

    Gómez M, Ruelas MEH, Welsh O, Arcaute HD, Ocampo-Candiani J. Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient. J Drugs Dermatol. 2007;6:337–9.

    PubMed  Google Scholar 

  142. 142.

    Zhang Y-H, Zhou Y, Ball N, Su M-W, Xu J-H, Zheng Z-Z. Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy. J Cutan Med Surg. 2010;14:185–8.

    PubMed  Article  Google Scholar 

  143. 143.

    Schreml S, Zeller V, Babilas P, Karrer S, Landthaler M, Szeimies R-M. Pityriasis rubra pilaris successfully treated with adalimumab. Clin Exp Dermatol. 2010;35:792–3.

    CAS  PubMed  Article  Google Scholar 

  144. 144.

    O’Kane D, Devereux CE, Walsh MY, Hoey SEH. Rapid and sustained remission of pityriasis rubra pilaris with adalimumab treatment. Clin Exp Dermatol. 2010;35:e155–6.

    PubMed  Article  Google Scholar 

  145. 145.

    Chiu H-Y, Tsai T-F. Pityriasis rubra pilaris with polyarthritis treated with adalimumab. J Am Acad Dermatol. 2013;68:187–8.

    PubMed  Article  Google Scholar 

  146. 146.

    Wassef C, Lombardi A, Rao BK. Adalimumab for the treatment of pityriasis rubra pilaris: a case report. Cutis. 2012;90:244–7.

    PubMed  Google Scholar 

  147. 147.

    Bravo EA, Carrion L, Paucar SM, Mendoza R, Rivera C. Successful treatment of pityriasis rubra pilaris with adalimumab—case report. Dermatol Online J. 2014;20:22374.

    PubMed  Google Scholar 

  148. 148.

    Kim BR, Chae JB, Park JT, Byun SY, Youn SW. Clinical remission of pityriasis rubra pilaris with adalimumab in an adolescent patient. J Dermatol. 2015;42:1122–3.

    PubMed  Article  Google Scholar 

  149. 149.

    Kitayama N, Nakamizo S, Kaku Y, Endo Y, Fujisawa A, Otsuka A, et al. Case of pityriasis rubra pilaris with annular pattern as an early manifestation. J Dermatol. 2017;44:478–9.

    PubMed  Article  Google Scholar 

  150. 150.

    Park S-H, Cho G, Park S-G. NF-κB activation in T helper 17 cell differentiation. Immune Netw. 2014;14:14–20.

    PubMed  PubMed Central  Article  Google Scholar 

  151. 151.

    Feldmeyer L, Mylonas A, Demaria O, Mennella A, Yawalkar N, Laffitte E, et al. Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol. 2017;153:304–8.

    PubMed  Article  Google Scholar 

  152. 152.

    Lernia VD, Ficarelli E, Zanelli M. Ineffectiveness of tumor necrosis factor-α blockers and ustekinumab in a case of type IV pityriasis rubra pilaris. Indian Dermatol Online J. 2015;6:207–9.

    PubMed  PubMed Central  Article  Google Scholar 

  153. 153.

    Lwin SM, Hsu C-K, Liu L, Huang H-Y, Levell NJ, McGrath JA. Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14. Br J Dermatol. 2017. https://doi.org/10.1111/bjd.15462 (Epub 2017 Mar 16).

    PubMed  Article  Google Scholar 

  154. 154.

    Eytan O, Sarig O, Sprecher E, van Steensel MA. Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14. Br J Dermatol. 2014;171:420–2.

    CAS  PubMed  Article  Google Scholar 

  155. 155.

    Paganelli A, Ciardo S, Odorici G, Pellacani G, Conti A. Efficacy of ustekinumab after failure of infliximab CT-P13 in a HLA-Cw6-positive patient affected by pityriasis rubra pilaris: monitoring with reflectance confocal microscopy (RCM) and optical coherence tomography (OCT). J Eur Acad Dermatol Venereol. 2017;31:e249–51.

    CAS  PubMed  Article  Google Scholar 

  156. 156.

    Byekova Y, Sami N. Successful response of refractory type I adult-onset pityriasis rubra pilaris with ustekinumab and acitretin combination therapy. J Dermatol. 2015;42:830–1.

    PubMed  Article  Google Scholar 

  157. 157.

    Chowdhary M, Davila U, Cohen DJ. Ustekinumab as an alternative treatment option for chronic pityriasis rubra pilaris. Case Rep Dermatol. 2015;7:46–50.

    PubMed  PubMed Central  Article  Google Scholar 

  158. 158.

    Di Stefani A, Galluzzo M, Talamonti M, Chiricozzi A, Costanzo A, Chimenti S. Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. J Dermatol Case Rep. 2013;7:5–9.

    PubMed  PubMed Central  Article  Google Scholar 

  159. 159.

    Wohlrab J, Kreft B. Treatment of pityriasis rubra pilaris with ustekinumab. Br J Dermatol. 2010;163:655–6.

    CAS  PubMed  Article  Google Scholar 

  160. 160.

    Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G, Bavetta M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013;169:458–63.

    CAS  PubMed  Article  Google Scholar 

  161. 161.

    Schuster D, Pfister-Wartha A, Bruckner-Tuderman L, Schempp CM. Successful treatment of refractory pityriasis rubra pilaris with secukinumab. JAMA Dermatol. 2016;152:1278–80.

    PubMed  Article  Google Scholar 

  162. 162.

    Gauci M-L, Jachiet M, Gottlieb J, Madeleine-Chambrin I, Rybojad M, Bagot M, et al. Successful treatment of type II pityriasis rubra pilaris with secukinumab. JAAD Case Rep. 2016;2:462–4.

    PubMed  PubMed Central  Article  Google Scholar 

  163. 163.

    Hunter GA, Forbes IJ. Treatment of pityriasis rubra pilaris with azathioprine. Br J Dermatol. 1972;87:42–5.

    CAS  PubMed  Article  Google Scholar 

  164. 164.

    Anand CL, Rathore SB. Therapeutic efficacy of azathioprine in pityriasis rubra pilaris. Indian J Dermatol Venereol Leprol. 1984;50:54.

    Google Scholar 

  165. 165.

    Usuki K, Sekiyama M, Shimada T, Shimada S, Kanzaki T. Three cases of pityriasis rubra pilaris successfully treated with cyclosporin A. Dermatology. 2000;200:324–7.

    CAS  PubMed  Article  Google Scholar 

  166. 166.

    Wetzig T, Sticherling M. Juvenile pityriasis rubra pilaris: successful treatment with ciclosporin. Br J Dermatol. 2003;149:202–3.

    CAS  PubMed  Article  Google Scholar 

  167. 167.

    Krase IZ, Cavanaugh K, Curiel-Lewandrowski C. Treatment of refractory pityriasis rubra pilaris with novel phosphodiesterase 4 (PDE4) inhibitor apremilast. JAMA Dermatol. 2016;152:348–50.

    PubMed  Article  Google Scholar 

  168. 168.

    Kerr AC, Ferguson J. Type II adult-onset pityriasis rubra pilaris successfully treated with intravenous immunoglobulin. Br J Dermatol. 2007;156:1055–6.

    CAS  PubMed  Article  Google Scholar 

  169. 169.

    Popova L, Darlenski R, Tsankov N. Penicillin and vitamin A as possible therapeutic agents in pityriasis rubra pilaris. J Dtsch Dermatol Ges. 2010;8:354–6.

    PubMed  Article  Google Scholar 

  170. 170.

    Ahn S-Y, Kim J-H, Ahn SK, Oh YS. Clinical improvement of pityriasis rubra pilaris with antibiotic therapy. Eur J Dermatol. 2011;21:106–7.

    PubMed  Google Scholar 

  171. 171.

    Coras B, Vogt TH, Ulrich H, Landthaler M, Hohenleutner U. Fumaric acid esters therapy: a new treatment modality in pityriasis rubra pilaris? Br J Dermatol. 2005;152:388–9.

    CAS  PubMed  Article  Google Scholar 

  172. 172.

    Haenssle HA, Bertsch HP, Emmert S, Wolf C, Zutt M. Extracorporeal photochemotherapy for the treatment of exanthematic pityriasis rubra pilaris. Clin Exp Dermatol. 2004;29:244–6.

    CAS  PubMed  Article  Google Scholar 

  173. 173.

    Hofer A, Müllegger R, Kerl H, Wolf P. Extracorporeal photochemotherapy for the treatment of erythrodermic pityriasis rubra pilaris. Arch Dermatol. 1999;135:475–6.

    CAS  PubMed  Article  Google Scholar 

  174. 174.

    Auffret N, Quint L, Domart P, Dubertret L, Lecam JY, Binet O. Pityriasis rubra pilaris in a patient with human immunodeficiency virus infection. J Am Acad Dermatol. 1992;27:260–1.

    CAS  PubMed  Article  Google Scholar 

  175. 175.

    Blauvelt A, Nahass GT, Pardo RJ, Kerdel FA. Pityriasis rubra pilaris and HIV infection. J Am Acad Dermatol. 1991;24:703–5.

    CAS  PubMed  Article  Google Scholar 

  176. 176.

    Bonomo RA, Korman N, Nagashima-Whalen L, Briggs J, Graham R, Salata RA. Pityriasis rubra pilaris: an unusual cutaneous complication of AIDS. Am J Med Sci. 1997;314:118–21.

    CAS  PubMed  Google Scholar 

  177. 177.

    De D, Dogra S, Narang T, Radotra BD, Kanwar AJ. Pityriasis rubra pilaris in a HIV-positive patient (Type 6 PRP). Skinmed. 2008;7:47–50.

    PubMed  Article  Google Scholar 

  178. 178.

    Lerebours-Nadal L, Beck-Sague CM, Parker D, Gosman A, Saavedra A, Engel K, et al. Severe, disfiguring, pityriasis rubra pilaris in a woman in the Dominican Republic: histopathologic diagnosis and response to antiretroviral therapy. J Int Assoc Provid AIDS Care. 2016;15:11–4.

    PubMed  Article  Google Scholar 

  179. 179.

    Perrin C, Durant JM, Lacour JP, Michiels JF, Dellamonica P, Ortonne JP. Horny perifollicular mucinosis. An atypical pityriasis rubra pilaris-like eruption associated with HIV infection. Am J Dermatopathol. 1993;15:358–62.

    CAS  PubMed  Article  Google Scholar 

  180. 180.

    Resnick SD, Murrell DF, Woosley JT. Pityriasis rubra pilaris, acne conglobata, and elongated follicular spines: an HIV-associated follicular syndrome? J Am Acad Dermatol. 1993;29:283.

    CAS  PubMed  Article  Google Scholar 

  181. 181.

    Menni S, Brancaleone W, Grimalt R. Pityriasis rubra pilaris in a child seropositive for the human immunodeficiency virus. J Am Acad Dermatol. 1992;27:1009.

    CAS  PubMed  Article  Google Scholar 

  182. 182.

    OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford: Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653. Accessed 15 Dec 2017.

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dingyuan Wang.

Ethics declarations

Funding

No funding support has been received for this study.

Conflict of interest

Dr. Hazel H. Oon is a clinical investigator for Janssen, Novartis, and Pfizer, and an advisory board member for AbbVie. Dr. Oon has also served as a speaker, advisory board member, and researcher for Galderma. Drs. V. C. L. Chong, D. Y. Wang, and W.S. Chong do not have any conflicts of interest to declare.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wang, D., Chong, V.CL., Chong, WS. et al. A Review on Pityriasis Rubra Pilaris. Am J Clin Dermatol 19, 377–390 (2018). https://doi.org/10.1007/s40257-017-0338-1

Download citation